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a  b  s  t  r  a  c  t
Presently,  many  consumer  products  contain  nano-sized  materials  (NMs)  to  improve  material  properties,
product quality  and  ease  of  use.  NMs  in  food  additives  and  in  cosmetic  articles  (e.g.,  tooth  paste)  may  be
taken up  by  the oral  route.  As  adverse  effects  of environmental  nanoparticles,  like  ultraﬁne  particles,  have
been reported,  consumers  worry  about  potential  risks  when  using  products  containing  NMs.  The  review
focuses  on  metal  and  metal  oxide  NMs  as  common  additives  in  tooth  paste  and  in food  industry  andeywords:
anomaterials
pithelial barriers
onsumer products
itanium dioxide
ilicon oxide
exposure  by  the  oral  route.  Testing  of  NMs  for  oral  exposure  is  very  complex  because  differences  in the
diet, in  mucus  secretion  and  composition,  in  pH,  in gastrointestinal  transit  time and  in  gastrointestinal
ﬂora  inﬂuence  NM  uptake.  Acellular  (mucus,  saliva)  and  epithelial  layer  of  the  orogastrointestinal  barrier
are described.  Expected  exposure  doses,  interaction  of  the  NMs  with  mucus  and  permeation  through  the
epithelium  as  well  as  in vivo  data  are  mentioned.  The  role  of in vitro  models  for  the  study  of  parameters
relevant  for  ingested  NMs  is  discussed.ilver © 2011 Elsevier Ireland Ltd. 
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. Introduction aim to improve cellular uptake and permeation of NMs  to improve
efﬁcacy, consumers and workers worry about the risks of non-
intended uptake. This article is focused on the evaluation of risk
Open access under CC BY-NC-ND license.Nanomaterials (NMs) are already included in many consumer
roducts (clothing, food, cosmetics, etc.) to improve handling,
tability and efﬁcacy of these products. In nanomedicine nanopar-
icles may  ﬁnd application in drug delivery, bio-imaging and
egenerative medicine. Whereas developments in nanomedicine
∗ Corresponding author at: Center for Medical Research, Medical University Graz,
tiftingtalstr. 24, A-8010 Graz, Austria. Tel.: +43 31638573011;
ax: +43 31638573009.
E-mail address: eleonore.froehlich@medunigraz.at (E. Fröhlich).
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Open access under CC BY-NC-ND license.by exposure to consumer products. Sources of NMs  relevant for
oral exposure comprise mainly cosmetics (sunscreen, lipsticks,
skin creams, toothpaste) and food (packaging, storage life sen-
sors, food additives, juice clariﬁers). Whereas NMs  in food are
intended to be ingested, nanoparticles for instance in cosmetics
and ingredients in food packaging may  accidently get into the
gastrointestinal tract. Major materials used in these products are:
silver, and metal oxides of zinc, silica, and titanium (Hansen et al.,
2008)). Nanosilver (Ag) is used in food packaging, amorphous
silica (SiO2) in food additives, titanium dioxide (TiO2), gold (Au),
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latinum (Pt) and zinc oxide (ZnO) nanoparticles in cosmetics,
specially sunscreens and toothpastes. According to the Woodrow
ilson Nanotechnology Consumer Products Inventory 2011 Ag
anoparticles are the most commonly used new NM in consumer
roducts followed by TiO2, ZnO, platinum (Pt) and silicium oxide
Ms  (http://www.nanotechproject.org/inventories/consumer/).
lthough gold NMs  are also used in cosmetics, food packaging,
everage and toothpaste their main applications are in the medical
eld.
Decrease of particle size in the nanoscale has been identiﬁed as
 main parameter for the increased toxicity of different materials.
olystyrene, for instance, is a very biocompatible polymer used in
ell culture. Nanoparticles, however, made from this material are
ytotoxic (Mayer et al., 2009). Accumulation of metal and metal
xide NMs  is seen also in lower animals such as fruit ﬂies, mus-
els, planktonic crustaceans, rainbow trouts and in plants (Harris
nd Bali, 2008; Pan and Wang, 2004; Panacek et al., 2011; Scown
t al., 2009; Zhu et al., 2009). In laboratory animals accumula-
ion of these particles especially in liver, spleen and kidney is seen
Bu et al., 2010; Chen et al., 2006; Kim et al., 2009, 2010; Meng
t al., 2007; Park et al., 2011; Wang et al., 2007a; Zhang et al.,
010a).
. Estimation of exposure
For physiologically relevant testing it would be important to
ave an approximate idea on the levels of NMs  to which humans
re exposed. This estimation is quite difﬁcult to make. Models based
n per capita daily intake of various foods combined with expected
istributions of chemicals or biological hazards in food work less
ell with NMs. The content of ingredients in form of nanoparticles
s generally not indicated in food, interaction with food compounds
s expected and physical changes of particles in the gastrointestinal
ract are likely.
Concentrations of metal and metal oxide in water and soil
ave been reported to reach 15.2 ng/l and 1.28 g/kg for TiO2,
.76 ng/l and 22.7 ng/kg for silver and 0.01 g/l and 0.093 g/kg
or ZnO, respectively (Gottschalk et al., 2009). Compared to
ther metal and metal oxide nanoparticles intake of TiO2 by
ood is relatively high: Powell et al. (2010) estimate inges-
ion of 5 mg  TiO2/person/d with an unknown part of it in
anoform. Total dietary intake only of nano-TiO2 is estimated to
e 2.5 mg/individual/d (0.036 mg/kg for a person of 70 kg; (Lomer
t al., 2000)). The intake of nano- and microparticles, however,
hows great variations: 0–112 mg/individual/d has been reported
Lomer et al., 2004). Metal and metal oxide nanoparticles can
ccumulate in plants (Harris and Bali, 2008) and in animals of
he food chain (Lankveld et al., 2010) and may  reach consid-
rably higher levels in humans. Consequently, chronic effects
ather than acute toxic effects on the human organism are
xpected.
NMs  are subjected to wide variations in the orogastrointesti-
al tract. pH variations from slightly acid to neutral in the oral
avity and in the small intestine to a very acid pH in the stom-
ch have a strong effect on surface charge of the particles and,
s a consequence, on agglomeration and cellular uptake. Differ-
nces in the pH between fasted and fed state are prominent in the
tomach (Horter and Dressman, 2001). Even in healthy individuals
astrointestinal transit is by far not constant and shows consider-
ble variation through the large intestine (Coupe et al., 1991). These
ffects are known to inﬂuence oral bioavailability of conventional
rugs but are even more important for the effects of NMs  because
Ms  readily adsorb proteins (Cedervall et al., 2007; Lynch et al.,
009), which on the one hand, determines biological actions and,
n the other, inﬂuence the dispersion of nanoparticles. Carboxyllogy 291 (2012) 10– 17 11
polystyrene particles, for instance show a high tendency of aggre-
gation, when suspended in FBS-containing medium (Mayer et al.,
2009; Xia et al., 2006). For other NMs  like carbon nanotubes, pro-
tein has a dispersing effect (Bihari et al., 2008; Heister et al., 2010;
Sager et al., 2007).
3. Uptake of particles
Permeation through the gastrointestinal barrier has been shown
for micro- and nanoparticles. The absorption is estimated to be
about 15–250 times higher for nanoparticles (Desai et al., 1996).
These barriers consist of cellular (epithelium) and acellular parts
(dead cells, mucus).
3.1. Acellular layers of the orogastrointestinal tract
For the entire tract, composed of the oral cavity, the esophagus,
the stomach and the intestine, mucus represents an efﬁcient acel-
lular barrier. Mucus consists of mucin proteins (highly glycosylated
extracellular proteins with characteristic gel-forming properties),
antiseptic proteins (lysozyme) and other proteins (lactoferrin),
inorganic salts and water. The major functions are the protection
and the lubrication of the underlying tissue.
The saliva, which is produced by the salivary glands, mainly con-
sists of water (up to 99.5%), inorganic salts, proteins, and mucins.
The high molecular weight mucin MG1  can bind to the surface of
the epithelium and build the so-called mucus layer, displaying the
acellular barrier of the oral cavity (Bykov, 1996, 1997). The thick-
ness of this mucus layer is different before and after swallowing
and measures between 70 and 100 m (Collins and Dawes, 1987;
Harris and Robinson, 1992; Lagerlof and Dawes, 1984). It displays
a thick gelatinous like layer, structured as a 3-dimensional net-
work with high water-holding capacity. It is highly viscoelastic
and displays a shear thinning gel acting as lubricant. It protects
the epithelial cell layers from pathogens, toxins and particles and
enables the exchange of nutrients, water and gases (Knowles and
Boucher, 2002).
Once substances are swallowed they pass the esophagus.
Esophageal glands, which are located throughout the esophagus,
secrete mucus directly onto the surface (Squier and Kremer, 2001).
Additionally, exocrine glands in the submucosa produce a secretion
with high bicarbonate concentration. This is necessary to neutralize
reﬂuxing stomach acid (Long and Orlando, 1999).
The mucus of the following parts, stomach and small and large
intestine, is mainly produced by intraepithelial cells. In the ﬁrst
part of the small intestine (duodenum) also exocrine glands in the
submucosa are located. The thickness of the mucus layer shows
high variations depending on the localization in the gastrointesti-
nal tract. The mucus layer demonstrates maximal thickness in the
stomach; thickness increases from proximal to distal parts of the
small and large intestine (Atuma et al., 2001; Matsuo et al., 1997).
Depending on the method used for the determination, the thick-
ness of the mucus layer shows marked variation. Fixation of the
tissues usually is accompanied by shrinking and lower values are
obtained. Endoscopic ultrasound measurements indicate thickness
of the mucus in the stomach of 897–1354 m and in the rectum of
730–1136 m (Huh et al., 2003) but variation may  be quite high
because the thickness is dictated by the interplay between mucus
secretion by goblet cells and mucus erosion by mechanical shear
and bacterial digestion, particularly in the lower gut (Corﬁeld et al.,Additionally, pH can vary. The pH of the mucus in the oral cavity
is estimated to range around pH 6.6. Gastric mucus shows a wide
pH range from 1 to 2 (luminal) to ∼7 (epithelial surface); (Schreiber
and Scheid, 1997)).
1 Toxicology 291 (2012) 10– 17
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Fig. 1. Different thickness and heterogeneity of orogastrointestinal epithelia. Com-
pared to the monostratiﬁed squamous epithelium of blood vessels (a) epithelia of
the orogastrointestinal tract are much thicker: stratiﬁed non-keratinized squamous
epithelium of the oral cavity and the esophagus (b) and simple columnar epithe-
lium present in the stomach, small and large intestine. All epithelia reside on a basal
lamina (BM). All epithelial layers are composed of different cell types. (d) In the
oral cavity, Langerhans cells (LC) and intraepithelial lymphocytes (L) in addition to
keratinocytes (KC) are present in the epithelial layer. The connective tissue below
the epithelial layer contains dendritic cells (DC), macrophages (M) and lymphocytes
(L). (e) The mucosa of the stomach consists of mucus-producing cells (MC), gastric
acid producing cells (parietal cells, PC), pepsinogen-producing cells (chief cells, CC)
and endocrine hormone producing enteroendocrine cells (EC). Cells of the immune
systems are not shown. (f) In the small intestine, enterocytes (EnC), microfold (M-
cells), goblet cells (GC), dendritic cells (DC) and intraepithelial lymphocytes (L) are
linked together by tight junctions (TJ). These junctions show small differences in2 E. Fröhlich, E. Roblegg / 
.2. Interaction of NMs  with the mucus layer
The characteristics facilitating the passage through human
ucus are relatively well known: electrostatic repulsion from neg-
tively charged sugar moieties favors the penetration of positively
harged hydrophilic molecules; the passage of lipophilic com-
ounds is slow (Avdeef and Testa, 2002).
It was thought that nanoparticles are incapable to penetrate
he mucus layer since recent studies demonstrated that speciﬁc
iruses, like the Norwalk virus with a size of 38 nm and human
apilloma virus with a size of 55 nm diffused in human mucus
s rapidly as they do in water (Olmsted et al., 2001; Saltzman
t al., 1994). The surface of viruses, which are able to permeate the
ucus, is densely coated with positive and negative charges, thus,
his net neutral surface charge prevents mucoadhesion (Olmsted
t al., 2001). Since the pore size in (cervical) mucus is approxi-
ately 100 nm,  it is suggested that small particles might also be
apable to diffuse through mucus. Olmsted et al. (2001) demon-
trated that small viruses diffused unhindered through mucus,
hereas polystyrene microspheres in a size of 59 nm and covalently
odiﬁed with carboxyl-groups, bound more tightly to mucins and
undled them into thick cables. Additional work by Dawson et al.
2003) reported that carboxyl and amine-modiﬁed polystyrene
articles (100, 200 and 500 nm)  were embedded in cystic ﬁbrosis
putum. The positively charged particles penetrated more rapidly
n the sputum than the negatively charged particles. Furthermore,
maller particles underwent a signiﬁcantly faster transport. Lai
t al. (2007) investigated polystyrene particles in a size range of
00–500 nm.  The surfaces of the particles were covalently modi-
ed with a high density of low M.W.  polyethylene glycol (PEG) and
he diffusion in human mucus was studied. The results demon-
trated that the neutral surface charge increased the diffusion rate
f all particles. The large particles (200 nm and 500 nm)  demon-
trated a 6-fold and 4-fold lower effective diffusion-coefﬁcient than
hat in water, whereas 100 nm particles were found to be immobile
n mucus. Other studies showed that 14 nm latex particles, which
ere slightly negatively charged, cross the distal colon mucus gel
ayer within 2 min  and 415 nm larges ones in 30 min, whereas 1 m
arges ones did not cross (Szentkuri, 1997). Non-biodegradable
atex particles can rapidly permeate human mucus when they are
oated with PEG. Surprisingly, 200 nm particles crossed the mucin
ayer faster than <100 nm NMs  (Wang et al., 2007b).  These ﬁndings
uggest that the surface charge plays a crucial role in the transport
ates of nanoparticles through a mucus layer.
Mucus lifetime is short and the fastest turnover (i.e., clearance
ime) is observed at surfaces with thinnest mucus layers. Thus,
anoparticles have to permeate quickly through this barrier to
each the underlying epithelia (Cone, 2009).
Local effects after oral exposure to NMs  include abnormal mucus
roduction, induced by TiO2 nanoparticles in cultured ChaGo-K1
ells (Chen et al., 2011) and by silver nanoparticles in vivo (Jeong
t al., 2010). Additionally, pH changes induced by NMs  can change
he pH-dependent aggregation of mucins (Bhaskar et al., 1991).
n addition, positively charged NMs  impede mucin swelling and
hereby increase viscosity (Chen et al., 2010).
.3. Epithelial layers of the orogastrointestinal tract
The epithelium generally represents the highest resistance
gainst the passage of chemical compounds and NMs. Epithe-
ial cells are polarized, they possess an apical surface facing an
nternal or external surface and a basal site, where they face the
nderlying tissue. Epithelia may  consist of several layers and may
ary in the height of the cells. Penetration through a monostrat-
ﬁed squamous epithelium, like in endothelia (Fig. 1a), is easier
han through the simple columnar epithelium in stomach andcomposition and location in the cell.
Figure adapted from Eom and Choi (2009).
intestine (Fig. 1b) and the squamous epithelium of the oral cavity
and the esophagus (Fig. 1c). The thickness of the non-keratinized
squamous epithelium in the oral cavity ranges between 550 and
800 m (Collins and Dawes, 1987; Harris and Robinson, 1992;
Lagerlof and Dawes, 1984). The squamous epithelium of the
esophagus shows a thickness of 300–500 m (Takubo, 2009). The
epithelium of the esophagus has the same structure as that of the
buccal mucosa but is thinner and less variable (Diaz del Consuelo
et al., 2005). The simple columnar epithelium in the gastrointestinal
tract measures 20–25 m (Atuma et al., 2001; Matsuo et al., 1997).
In general, only one cell type forms the structural basis of the bar-
rier: keratinocytes for the oral cavity and the esophagus, gastric
Toxicology 291 (2012) 10– 17 13
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Fig. 2. Active uptake mechanisms of NMs  into cells. Major routes are
macropinocytosis, clathrin-mediated endocytosis and caveolae-mediated and
non-clathrin, non-caveolae mediated uptake. The later are subdivided into
RhoA- (or IL-2R-) dependent endocytosis, Cdc42/Arf1 or clathrin-independent
cargo/glycophosphatidylinositol (GPI)-anchored protein enriched compartment-
dependent (GEEC) endocytosis, Arf6- dependent endocytosis and ﬂotillin-
dependent endocytosis. The content of macropinosomes (MP), clathrin-coated
vesicles (CC) and GEEC is transported via early endosomes (EE) and late endosomes
(LE) to lysosomes (L). Material taken up by caveolae-mediated endocytosis is trans-
ported via caveolosomes (Cav) either to the endoplasmic reticulum (ER) or to early
endosomes. NMs may  be removed from the cells by exocytotic vesicles (EV). Early
endosomes may  also fuse with the plasma membrane directly or through recyclingE. Fröhlich, E. Roblegg / 
pithelial cells for the stomach and enterocytes for the small and
arge intestine. The epithelial cells are linked together by intercel-
ular junctions, which give the epithelial layer mechanical strength
nd restrict passage between cells. In the oral mucosa immune cells
Langerhans cells, lymphocytes) are embedded in the keratinocytes
ayer (Fig. 1d). The epithelium of the stomach contains mucus pro-
ucing mucus neck cells, pepsinogen-producing gastric chief cells,
astric acid and intrinsic factor producing parietal cells and a vari-
ty of hormones (gastrin, serotonin, somatostatin, etc.) producing
nteroendocrine cells (Fig. 1e). In the small intestine, cells belong-
ng to the immune system (M-cells), enteroendocrine cells and
oblet cells are embedded in a layer of enterocytes (Fig. 1f). M-cells
re preferentially located in the epithelium overlying the Peyer’s
atches, which is also called Follicle Associated Epithelium (FAE),
nd deliver foreign substances to the underlying tissues (mucosa
ymphoid) to induce immune responses (Gerbert et al., 1996). M-
ells, however, are also a potential portal for nanoparticles. The
pithelium of the large intestine consists of enterocytes and goblet
ells. When different cell types adjoin the barrier function of the
pithelium is altered because the location and structure of these
unctions differ between the cell types (Eom and Choi, 2009). All
pithelia reside on a basal membrane, which separates them from
he underlying connective tissue containing capillaries, lymph ves-
els, lymph follicles and peripheral nerves. To reach the systemic
irculation by capillaries NMs  have also to cross the basal mem-
rane and the connective tissue.
.4. Permeation through orogastrointestinal barriers in vitro
Epithelia can be permeated either by passage through the cells
transcellular) or by passage between the cells (paracellular). Phys-
ological methods to evaluate interactions with biological barriers
nd to predict the effect of nanoparticles are highly demanded.
tudies addressing permeation usually use transwell systems,
here cells are cultured on ﬁlters. Moreover, diffusion-cells can be
sed to evaluate the penetration/permeation of NMs  across excised
issues (Sudhakar et al., 2006). Studies on cell monolayers show that
olystyrene particles can readily permeate the alveolar epithelium
Yacobi et al., 2008). By contrast, the rate of permeation of ente-
ocyte (Caco-2 cell) monolayers by polystyrene particles without
urface coating appears low (Geiser et al., 2005; Pietzonka et al.,
002). Gaumet et al. (2009) showed that small polystyrene particles
ere observed intracellularly in Caco-2 cells. Also TiO2 nanopar-
icles appear to cross Caco-2 monolayers without disruption of
unctional complexes and without causing cytotoxicity (Koeneman
t al., 2010).
Since the plasma membrane of the cells forming the epithelial
arrier is lipophilic, lipophilic substances are taken up passively
y the transcellular route whereas hydrophilic drug compounds
se the paracellular route. The penetration area of the paracellular
oute is extremely small compared to the transcellular route and
estricted to polar substances below 1000 D. Paracellular transport
s only passive. Nanoparticles are not expected to be able to use
he paracellular route, because they are considerably larger than
000 D. To get an idea about the relation of molecular weight and
ize: serum albumin with 66 kD has an almost sphere-like shape of
 nm × 8 nm × 8 nm (Takizawa et al., 1992).
Transcellular passage by passive diffusion appears to be rare:
lthough passage of cells by 22 nm TiO2 particles was suggested to
ccur by passive diffusion (Geiser et al., 2005), other researchers
escribed that Au-nanoparticles in sizes of 5–8 nm could not enter
ells by passive diffusion ((Stoeger et al., 2006)). Active uptake by
ndocytosis is the likely mode of cellular uptake for metal and
etal oxide NMs. Several endocytotic routes have been character-
zed, which are classiﬁed according to the coating with clathrin
nd the involvement of dynamin in the uptake. Main mechanismsendosomes (RE). In polarized cells transcytosis occurs via transport vesicles (TV).
Cyto: cytoplasm.
are termed clathrin-mediated endocytosis, macropinocytosis and
caveolae-dependent. Different classiﬁcations are used for the
clathrin-independent and caveolae-independent routes. The clas-
siﬁcation by Sahay et al. (2010) is mainly based on the
GTPases involved (Arf6-dependent, Cdc42/Arf1-dependent and
RhoA-dependent endocytosis) and on the coat protein (Flotillin-
dependent). Another nomenclature employs the term clathrin-
independent carriers/glycophosphatidylinositol (GPI)-anchored
protein enriched compartment (GEEC)-type endocytosis as
synonym for Cdc42/Arf1-dependent endocytosis and IL-2R-
dependent endocytosis for RhoA-dependent endocytosis (Doherty
and McMahon, 2009). Independent of the route of entry, the car-
gos are mainly transported via endosomes to lysosomes (Fig. 2).
Non-functionalized silver, TiO2 and SiO2 particles are mainly taken
up by clathrin-mediated endocytosis (Chung et al., 2007; Greulich
et al., 2011; He et al., 2009; Huang et al., 2005; Singh et al., 2007;
Sun et al., 2008).
Nanoparticles can leave the cells either by transcytosis or by
exocytosis. Exocytosis of nanoparticles is not well studied and con-
ﬂicting results were obtained: exocytosis of quantum dots was
not consistently seen in the studies (Clift et al., 2008; Jiang et al.,
2010). Transcytosis can occur through receptor-mediated uptake
or via adsorptive-mediated uptake. Receptors for BSA, transferrin
and opioid peptides functionalized NMs  are expressed on sev-
eral cell types and BSA-coated nanoparticles have been shown to
transcytose through endothelial cells (Wang et al., 2009). For the
gastrointestinal tract, however, this type of uptake is not relevant.
Absorptive-mediated transcytosis is mediated by the interaction
of positively charged substances with anionic sites of the plasma
membrane: cationic nanoparticles had a greater potential than
neutral or negatively charged ones (Harush-Frenkel et al., 2008).
Additionally uncoated, not positively charged TiO2 nanoparticles
can cross the intestinal epithelium by the transcellular route
(Koeneman et al., 2010).
As mentioned in Section 3.3,  the epithelium of the gastrointesti-
nal tract is composed of various cell types and permeation through
some types of cells is easier than through others. This situation
can be mimicked also in vitro. Kerneis et al. (1997) constructed an
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Table  1
Oral exposure of rodents and broiler chicken (*) to metal and metal oxide particles contained in consumer products. The doses were delivered either by gavage and intragastrial
injection (mg/kg) or in the drinking water (ppm, mg/l).
Particle (size) Dose Effect Reference
Ag (14 nm)* 5–15–25 ppm for 42 d Indication for oxidative stress in bood and for
decreased immune function
Ahmadi and Kurdestany (2010)
Ag  (14 nm)* 300–600–900 ppm for 56 d No effect on blood chemistry and blood count,
weight reduced at 900 ppm, no change in organ
histology
Ahmadi (2009),  Ahmadi et al. (2009)
Ag  (15 nm) 2.5 mg/kg for 3 d Local inﬂammation of the stomach Cha et al. (2008)
Ag  (56 nm) 30–125–500 mg/kg for 90 d Liver damage at 125 mg/kg Kim et al. (2010)
Ag  (60 nm) 30–300–1000 mg/kg for 28 d Highest tissue levels in stomach, kidney, liver and
lungs, LOAEL of 300 mg/kg
Kim et al. (2008)
Ag  (22–42–71–323 nm)  1 mg/kg for 14 d Indication for liver damage, activation of
B-lymphocytes
Park et al. (2010)
Au  (4–10–28–58 nm) 200 mg/l for 7 d Accumulation of smaller particles in kidney, liver,
spleen, lung, brain. Larger particles accumulated in
the GI tract
Hillyer and Albrecht (2001)
Au  (13.5 nm)  137.5–2200 g/kg for 14–28 d Spleen enlargement, damage of intestinal mucosa Zhang et al. (2010b)
Au  (14 nm)  75–150–300 ppm for 28 d No changes in blood chemistry, body weight and
organ histology
Dhar et al. (2010)
Pt  (1–6 nm)  9.75 mg/kg for 5 d Little effect on protein expression Katao et al. (2011)
TiO2 (5 nm)  62.5–125–250 mg/kg for 30 d Reduction of body weight, indication for liver
damage, pathological blood count at ≥125 mg/kg
Duan et al. (2010)
TiO2 (25 nm)  60–600 mg/l for 5 d DNA-damage in various tissues Trouiller et al. (2009)
TiO2 (<50 nm)  0.16–0.4–1 g/kg Indication for liver damage, disturbance of energy
and amino acid metabolism at 1 g/kg
Bu et al. (2010)
TiO2 (50–120 nm)  5 g/kg for 7 d Liver and kidney damage only in combination with
lead acetate
Zhang et al. (2010a)
TiO2 (25–80–155 nm)  Single dose of 5 g/kg Minimal uptake, indication for liver and kidney
damage
Wang et al. (2007a)
TiO2 (140 nm)  Single dose of 175–550–1750–5000 mg/kg No mortality, no gross lesions at necropsy Warheit et al. (2007)
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pTiO2 (500 nm)  12.5 mg/kg for 10 d Uptak
spleen
ZnO  (120 nm) 5  g/kg for 14 d Distri
ntestinal in vitro co-culture model consisting of Caco-2 on inverted
nserts and immune cells isolated from murine Peyer’s patches. The
rst M-cell model was developed by Gullberg et al. (2000) using
aco-2 (normally oriented inserts) and Raji cells. The group of des
ieux (des Rieux et al., 2005, 2007) improved the in vitro epithelial
ell model and investigated the inﬂuence of the physicochemi-
al properties on the transport (mechanism) of nanoparticles by
-cells. To this aim, Caco-2 and Raji B cells were co-cultured in tran-
wells (to induce M-cell development). Both negatively charged
nd positively charged polystryrene particles were taken up by M-
ells via the transcellular route. The transport was dependent on the
oncentration, the temperature and the size. Furthermore, the pres-
nce of cationic groups enhanced the transport due to electrostatic
nteractions between the particle surface structure and the cell sur-
ace. Compared with investigations carried out with a monoculture,
he particle transport in the transwell system was 50-fold higher
des Rieux et al., 2005, 2007; Ruponen et al., 2004). Gullberg et al.
2006) studied the FAE and demonstrated that integrin-targeted
anoparticles are preferentially transported across the FAE into
he Peyer’s patches. These data suggest that integrin interaction is
 dominating mechanism for improved particle uptake across the
AE. Although M cells are also located outside the FAE (villous-M
ells), the transport of antigens and/or nanoparticles is mainly car-
ied out by the FAE-M cells, since the mucus layer limits the particle
ptake across the villous epithelium (Jang et al., 2004).
Some research has been carried out so far on the buccal mucosa.
he permeability through excised porcine buccal mucosa was
nvestigated with Franz diffusion cells to study the transport of
anoparticles across this tissue. The results demonstrated that
olystyrene particles penetrated into the tissue due to endocytotic
echanisms (Roblegg et al., 2011). The most relevant barrier for
egatively charged particles was the mucus layer together with
he top third region of the epithelium. Positively charged parti-
les, however, showed no interaction with the mucus layer and
enetrated into deeper regions of the epithelium.articles 7% in GI tract, 5% in liver, lung,
t, kidney
Jani et al. (1994)
 in bone, liver, kidney, pancreas Wang et al. (2008)
3.5. Permeation through barriers in vivo
Uptake of metallic silver from the environment is 10–20% in GI
mainly in the stomach and the duodenum (Armitage et al., 1996).
Recovery of 10% of the applied dose was also obtained for 60 nm
polystyrene particles dosed at 14 mg/kg for 5 d to rats (Hillery et al.,
1994). Fluorescent polystyrene particles in sizes between 2 and
20 m are found in the Peyer Plaques of the ileum; 2 m parti-
cles in addition also in mesenterial lymph nodes (Carr et al., 1996).
The accumulation in the lymphatic tissues started 5 min  after the
application and was  higher in proximal than in distal lymph nodes
(Hazzard et al., 1996). Jani et al. (1990) evaluated the effect of the
different sizes (50–100–200–300–1000–3000 nm) of polystyrene
particles on gastrointestinal uptake. They found a size-dependent
decrease of the uptake from 34% for 50 nm particles to 26% for
100 nm particles. The uptake rate of the larger particles was  mini-
mal. 6.6% of the dose was detected in liver, spleen, blood and bone
marrow compared to 0.8% for 1000 nm particles.
In addition to particle size, dose and duration of the exposure
are important for the interpretation of the data (Overview pro-
vided in Table 1). Independent from the material used, NMs up
to 100 nm distribute into the organism after one single applica-
tion (Jani et al., 1990). When multiple applications are performed
also larger particles distribute outside of the gastrointestinal sys-
tem (Jani et al., 1994). High dosing, species differences, choice of
the tracer and methodology used for organ distribution compli-
cate comparisons between different studies, as well as conclusions
on nanoparticle effects. For instance, local effects at the gastroin-
testinal mucosa, liver and kidney damage and impairment of the
immune system have been reported. Based on environmental data
for nano-TiO2, concentrations much higher than 0.4 mg/kg for acute
toxicity appear unrealistic (Lomer et al., 2000). As many metals and
metal oxides may  accumulate, the evaluation of higher doses is
justiﬁed. Nevertheless, data from repeated applications of ≥1 g/kg
are not physiologically relevant. In broiler chicken hatchlings,
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hich were treated with doses below 250 ng/kg silver nanoparti-
les (Ahmadi and Kurdestany, 2010; Ahmadi, 2009; Ahmadi et al.,
009), adverse effects were already detected at these low concen-
rations. The higher toxicity of the silver nanoparticles may  either
e due to interspecies differences or to the low age of the chicken.
or correct tracing of the organ distribution the choice of the label
nd the mode of detection appear important. In the study of Jani
t al. (1990) the label was potentially not stable and the localiza-
ion of the label may  not correspond to that of the particles. If NMs
re only detected by chemical analysis it is not clear if they are
ccumulated in a dissolved form or as intact particles.
. Action on compromised barriers
Few data have been published regarding the permeation
hrough diseased barriers. Changes in mucus composition induced
y Ag nanoparticles (Jeong et al., 2010), polystyrene particles and
iesel exhaust increased mucus permeability and permeation of
mall molecules by a factor of 5 (McGill and Smyth, 2010). The
dherence of polystyrene nanoparticles to inﬂamed colonic mucosa
as much higher than to normal mucosa (Lamprecht et al., 2001).
lso in the elaborated co-culture in vitro model developed by
eonhard et al. (2010) smaller particles (50 nm) polystyrene par-
icles adhered better to the inﬂamed monolayer and were taken up
nto the cells, whereas larger particles only adhered to the cell sur-
ace. Inﬂammation appears to increase uptake and permeation of
Ms  in vitro and in vivo. Inﬂammation caused by Yersinia pseudo-
uberculosis increases the uptake of 100 nm carboxyl polystyrene
articles in cell monolayers and in intestinal biopsies (Ragnarsson
t al., 2008). In contrast to that, in the in vitro study by Leonhard
t al. (2010) no inﬂuence on the translocation of the polystyrene
articles was observed. Since in the in vitro studies lipopolysaccha-
ide and not intact bacteria were used, effects by the living bacteria
n cells, mucus production and/or viscosity may  account for the
bserved differences.
. Conclusion
The assessment of penetration and biological effects of ingested
Ms  presents many problems because it is very complex. Inter-
ndividual differences in the composition, pH and thickness of
he mucus layer, in the gastrointestinal ﬂora and in gastrointesti-
al passage time complicate in vivo experiments. In the study of
oeschner et al. (2011) on organ distribution of 60 nm Ag nanopar-
icles great inter-individual variations were noticed although all
nimals were fed the same diet. Also differences in the diet are
mportant.
For in vivo testing, rodents also may  not be ideal models.
lthough men  and rodents are omnivorous, function (e.g., region
or absorption of food) and morphology of the gastrointestinal tract
e.g., absence of gall bladder in rats) show considerable differences
etween rodents and humans (Kararli, 1995).
Apart from permeating themselves, NMs  may  have perme-
tion enhancing properties for other substances. This phenomenon
ermed as ‘Trojan horse’ effect, was ﬁrst identiﬁed for metal
anoparticles. Whereas plasma membranes restrict the cellular
ccess for metal ions like silver cations, silver nanoparticles were
eadily internalized and intracellular silver concentrations were
uch higher than for silver ions (Navarro et al., 2008). Studies
or uptake and toxicity should, therefore, include AgNO3 for silver
anoparticles (Trojan horse effect) or bulk material.Other important effects are linked to the tendency of NMs
o absorb macromolecules. By adsorption of organic compounds
lso unintended molecules (undigested and unmetabolized com-
ounds) may  be absorbed by the gastrointestinal tract. On the otherlogy 291 (2012) 10– 17 15
hand adsorption to NMs  may  also prevent the uptake of necessary
molecules (Alkhamis et al., 2009). Absorption may  also be altered
by a changed metabolization by enterocytes. Polystyrene and sil-
ver particles have been shown to inhibit the activity of cytochrome
P450 enzymes (Fröhlich et al., 2010; Lamb et al., 2010).
To obtain more information about penetration of the orogas-
trointestinal barriers and subsequent biological effects physiolog-
ically relevant in vitro models should be used, which enable the
controlled variation of the most important parameters involved.
Particle properties should be recorded in mucus of different pH and
the extent of binding to proteins and other macromolecules should
be studied. Physiologically relevant in vitro (co-culture) models
including mucus should be established to investigate also the effect
of changed mucus structure, inﬂammation and pH changes. It is
obvious that also in vivo experiments are needed but without a
good knowledge on the inﬂuence of the orogastrointestinal varia-
tions on particle parameters and penetration in vivo data may  be
difﬁcult to interpret.
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